論文: PharmaVoice
The article discusses the latest developments in implementing President Donald Trump’s “most favored nation” policy, which aims to reduce US drug prices to levels aligned with those in other countries. This policy directs pharmaceutical manufacturers to voluntarily lower prices or face enforced measures. While the HHS has set specific price targets, its ability to enforce these policies remains limited, prompting skepticism within the industry. Additionally, new Congressional reforms and global comparisons are shaping ongoing discussions about drug pricing in the United States.
Published: 2025年5月27日
Learn more about Certara’s Market Access, Pricing and Reimbursement services
Need help assessing the potential impact of the ‘Most Favored Nation’ drug pricing policy? Certara’s Market Access, Pricing and Reimbursement experts are standing by to offer their perspective as you consider strategies across your global portfolio.
